Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) ...

They include MET-233i, an injectable amylin analog that is Metsera’s answer to the sector’s search for a once-monthly dosing ...

Losing weight on GLP-1 drugs like Ozempic isn't guaranteed. Experts reveal how to tell if yours isn't working and the next steps you should take to reach your weight loss goals.

You can’t go far lately without seeing news and social media coverage of GLP-1 (glucagon-like peptide-1) receptor agonists like Ozempic®, Wegovy®, Mounjaro®, and Zepbound®. While Ozempic can ...

and author of the best-selling books How Not to Die, How Not to Diet, and How Not to Age, turned his attention to the latest research on GLP-1 weight-loss drugs in his new book, OZEMPIC ...

DehydraTECH clinical test article manufacturing has been completed KELOWNA, BC / ACCESSWIRE / November 13, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW) (the "Company" or "Lexaria"), a global ...

Lexaria is looking forward to discovering whether DehydraTECH-CBD studied alone, or together with DehydraTECH-GLP-1, in humans might offer some benefit of improved weight loss and/or reduced ...

The odds for aspiration is greatest in the first weeks after a GLP-1 med is prescribed, since the delay in stomach emptying ...

Current GLP-1-based obesity medications are effective in achieving 15-20% weight loss, but up to 40% of this ... positioning it as a 'best-in-class' candidate in obesity treatment.

Michael Greger, M.D., FACLM, the internationally renowned nutrition expert, physician, founder of NutritionFacts.org, and ...